Cover Image
Market Research Report

Schizophrenia - Market Insights, Epidemiology and Market Forecast - 2030

Published by DelveInsight Business Research LLP Product code 963732
Published Content info 391 Pages
Delivery time: 1-2 business days
Price
Back to Top
Schizophrenia - Market Insights, Epidemiology and Market Forecast - 2030
Published: October 14, 2020 Content info: 391 Pages
Description

DelveInsight's 'Schizophrenia-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU5(Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Schizophrenia market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Schizophrenia market size from 2017 to 2030. The report also covers current Schizophrenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Schizophrenia Disease Understanding and Treatment Algorithm

Overview

Schizophrenia is a severe mental disorder in which people interpret reality abnormally. It may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning, and can be disabling. Contrary to public perception, schizophrenia is not split personality or multiple personalities. Besides, it is not caused by childhood experiences, poor parenting, or lack of willpower, nor the symptoms are identical in each patient. In addition, the vast majority of people with schizophrenia are not violent and do not pose a danger to others. The most common form is paranoid Schizophrenia or Schizophrenia with paranoia. People with paranoid schizophrenia have an altered perception of reality. They may see or hear things that do not exist, speak in strange or confusing ways, believe that others are trying to harm them or feel like they are being watched continuously. This can cause relationship problems, disrupt normal daily activities like bathing, eating, or running errands, and lead to alcohol and drug abuse in an attempt to self-medicate.

Experts believe illness results from a combination of genetic and environmental causes. The chance of having Schizophrenia is 10% if an immediate family member (a parent or sibling) has the illness. The risk is as high as 65% for those who have an identical twin with Schizophrenia.

Schizophrenia Diagnosis

Diagnosing Schizophrenia is not easy. Sometimes using drugs, such as methamphetamines or LSD, can cause a person to have Schizophrenia-like symptoms. The difficulty of diagnosing this illness is compounded by the fact that many people who are diagnosed do not believe they have it. Lack of awareness is a common symptom of people diagnosed with Schizophrenia and greatly complicates treatment.

While there are no single physical or lab tests that can diagnose Schizophrenia, a health care provider who evaluates the symptoms and the course of a person's illness over 6 months can help ensure a correct diagnosis. The health care provider must rule out other factors such as brain tumors, possible medical conditions, and other psychiatric diagnoses, such as bipolar disorder. To be diagnosed with Schizophrenia, a person must have two or more of the following symptoms occurring persistently in the context of reduced functioning:

  • Delusions
  • Hallucinations
  • Disorganized speech
  • Disorganized or catatonic behavior
  • Negative symptoms

Delusions or hallucinations alone can often be enough to lead to a diagnosis of Schizophrenia. Identifying it as early as possible improves greatly a person's chances of managing the illness, reducing psychotic episodes, and recovering. People who receive good care during their first psychotic episode are admitted to the hospital less often and may require less time to control symptoms than those who don't receive immediate help. The literature on the role of medicines early in treatment is evolving, but it is known that psychotherapy is essential.

The doctor or therapist bases his or her diagnosis on the person's report of symptoms and his or her observation of the person's attitude and behavior.

The doctor or therapist then determines if the person's symptoms point to a specific disorder as outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which is published by the American Psychiatric Association and is the standard reference book for recognized mental illnesses. According to the DSM-5, a diagnosis of Schizophrenia is made if a person has two or more core symptoms, one of which must be hallucinations, delusions, or disorganized speech for at least one month. The other core symptoms are gross disorganization and diminished emotional expression. Other DSM-5 criteria for a diagnosis of Schizophrenia include:

  • The level of work, interpersonal relations, or self-care is significantly below what it was before the start of symptoms.
  • Signs of disturbance that have lasted at least 6 month
  • Schizoaffective disorder and depressive or bipolar disorders with psychotic symptoms have been ruled out.
  • The disturbance is not caused by substance abuse or another medical condition (Cleveland Clinic, 2018).

Schizophrenia, like most psychiatric diagnoses, remains a syndromic concept. The use of operational criteria, such as those embodied in DSM-510 or the WHO International Classification of Diseases (ICD), has provided a reliable approach to psychiatric diagnoses in the clinic. However, the assumption that the clinical syndromes defined in this way represent valid disease entities with distinct underlying causes and pathogenesis is increasingly being seen as having impeded research. Indeed, psychiatric diagnoses have the unusual feature of being simultaneously too broad and too narrow.

Schizophrenia Treatment

Schizophrenia is a lifelong condition, but effective treatment can help a person manage the symptoms, prevent relapses, and avoid hospitalization. It requires lifelong treatment, even when symptoms have subsided. The illness requires a combination of treatments, including medication (antipsychotics), psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT). Currently approved pharmacologic agents focus mainly on modulating dopamine, leaving patients with Schizophrenia to cope with considerable residual symptoms. Suboptimal treatment, significant AEs, and challenges related to nonadherence create a need for new agents to manage Schizophrenia better. The focus of treatment in Schizophrenia changes as individuals enter different phases of the illness. Antipsychotic medications are commonly used for the treatment and is grouped into two categories, one is "second-generation" (or "atypical") that is applied to clozapine-all antipsychotics first marketed after clozapine was approved in 1989-, and other is "first-generation" which is applied to antipsychotics marketed previously. Recent clinical research, however, has strongly suggested that the distinction between first- and second-generation antipsychotics has questionable validity and is confusing. The pharmacologic properties, therapeutic effects, and adverse effects are not distinguished between and are heterogeneous within the groups. According to the American Psychiatric Association, second-generation (atypical) antipsychotics (SGAs)-except for clozapine-are the agents of choice for first-line treatment of Schizophrenia. Some antipsychotics may be given as an intramuscular or subcutaneous injection and are also known as long-acting injectable antipsychotics. They are usually given every 2-4 weeks, depending on the medication.Various therapies like Psychotherapy and psychosocial therapy are given to cope up with the symptoms.

Schizophrenia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of schizophrenia, Diagnosed Prevalent cases of schizophrenia, Gender-specific Diagnosed Prevalent cases of schizophrenia, Age-specific Diagnosed Prevalent cases of schizophrenia, Severity-specific Diagnosed Prevalent cases of schizophrenia scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpses of the Schizophrenia epidemiology in the 7MM.

  • Total prevalent population of schizophrenia in the 7MM was 5,616,463 in 2017. These cases of schizophrenia in the 7MM is expected to increase throughout the study period, i.e., 2017-2030.
  • Total diagnosed prevalent population of schizophrenia in the 7MM was observed to be 3,811,974 in 2017.

Country Wise-Schizophrenia Epidemiology

The epidemiology segment also provides the Schizophrenia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Schizophrenia Drug Chapters

This segment of the Schizophrenia report encloses the detailed analysis of the mid- and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

Schizophrenia Emerging Technique

Doria (risperidone ISM): Rovi Pharmaceuticals Laboratories

Doria is a monthly intramuscular injection that does not require loading doses or concurrent oral risperidone. It is a new long-acting injectable (LAI) intramuscular formulation of risperidone, for monthly administration without oral supplementation. As compared to all the other emerging therapies that are expected to be launched in the forecasted period, Doria is the only that is expected to be launched as an intramuscular ROA. As reaches suggest that the intramuscular route of administration is more effective compared to oral, hence Doria is expected to generate a highest market share compared to other therapies.

SEP-363856: Sunovion/PsychoGenics

SEP-363856 is an orally active, novel trace amine-associated receptor 1 (TAAR1) agonist with serotonin 1A (5-HT1A) agonist activity that is under investigation for the treatment of schizophrenia and other psychiatric conditions. SEP-363856 was discovered utilizing a high throughput, high content, mouse-behavior phenotyping platform, in combination with in vitro screening, aimed at developing non-D2 (anti-target) compounds that could nevertheless retain efficacy across multiple animal models sensitive to D2-based pharmacological mechanisms. SEP-856 demonstrated broad efficacy in putative rodent models relating to aspects of Schizophrenia, including phencyclidine (PCP)-induced hyperactivity, prepulse inhibition, and PCP-induced deficits in social interaction. In addition to its favorable pharmacokinetic properties, lack of D2 receptor occupancy, and the absence of catalepsy, SEP-856's broad profile was further highlighted by its robust suppression of rapid eye movement sleep in rats. Preclinical models suggest that SEP-363856 has the potential to treat the positive and negative symptoms of Schizophrenia. SEP-363856 is being studied in a global phase III development program for Schizophrenia

Roluperidone (MIN-101): Minerva Neurosciences

Roluperidone is meant to block a specific subtype of serotonin receptor called 5-HT2A. When 5-HT2A is blocked, certain symptoms of schizophrenia, such as hallucinations, delusions, agitation, thought, and movement disorders, as well as the side effects associated with antipsychotic treatments, can be minimized. Additionally, blocking 5-HT2A promotes slow-wave sleep, a sleep stage often disrupted in patients with Schizophrenia. The drug is also meant to block a specific subtype of sigma receptor called sigma2, which is involved in movement control, psychotic symptom control, learning, and memory. Blocking sigma2 also modulates other neurotransmitters in the brain, in particular dopamine, which is important as individuals with Schizophrenia often have elevated levels of dopamine in their brains. Blocking sigma2 also increases calcium levels in neurons in the brain, which can improve memory. In December 2017, the company announced the screening of the first patient in the pivotal Phase III clinical trial of Roluperidone (Study MIN-101C07) as monotherapy for negative symptoms in patients diagnosed with Schizophrenia. However, the trial did not meet the primary and key secondary endpoints

Dexmedetomidine (BXCL501): BioXcel Therapeutics

BXCL501 is a potential first-in-class, a proprietary sublingual thin film of dexmedetomidine, and a selective alpha-2a receptor agonist for the treatment of acute agitation. The drug directly targets a causal agitation mechanism and has observed anti-agitation effects in multiple clinical studies across multiple neuropsychiatric indications. The drug is the company's most advanced neuroscience clinical program, being developed initially for the treatment of acute agitation in patients with schizophrenia and bipolar disorders. BXCL501 is designed to be easy to administer and has shown a rapid onset of action in clinical studies. It has the potential to generate a calming effect without producing excessive sedation

More products and detail in the report…

List to be continued in the report……

Schizophrenia Market Outlook

With no cure for schizophrenia, the main goals of schizophrenia treatment include symptom targeting and prevention of relapsed cases. Pharmacological therapy plays a vital role in the treatment of this disease, where many mono and combination pharmacological therapies are available for treating schizophrenia symptoms. Antipsychotics are the first choice among psychotropic agents used to treat schizophrenia. For some patient groups, treatment strategies include the combination of neuroleptics and antiepileptics. As the prevalence of depressive symptoms in patients with schizophrenia is relatively high, antidepressants are also often prescribed. Moreover, some evidence supports the use of combination therapy with antipsychotics and benzodiazepines. Finally, the use of certain anticholinergic drugs in conjunction with antipsychotics has been identified as an essential milestone in the treatment of schizophrenia.

The treatment options for schizophrenia include medication (antipsychotics), psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT). Currently available antipsychotics, which are thought to work primarily via modulation of dopamine, largely target positive symptoms. As a result, many patients are left with residual negative and cognitive symptoms. New research combined with an increased understanding of the etiology and pathophysiology of schizophrenia is leading to the development of novel agents to improve schizophrenia management and to address the above-mentioned gaps.

Antipsychotic (AP) medications are recommended as first-line treatment for schizophrenia and are classified as first-generation antipsychotics (FGA; or typical APs) and second-generation antipsychotics (SGA; or atypical APs). For each generation, both oral antipsychotics (OAP) and long-acting injectable therapies (LAI) are available.

There are several FDA approved products for schizophrenia treatment, including Rexulti (brexpiprazole, Otsuka America Pharmaceutical/ Lundbeck), Caplyta (lumateperone/ ITI-007, Intra-Cellular Therapies), Latuda (lurasidone hydrochloride, Sunovion Pharmaceuticals/Sumitomo Dainippon Pharma), Vraylar (cariprazine, Gedeon Richter/AbbVie), Saphris (asenapine, Merck/AbbVie/Schering-Plough Corporation/Allergan), Abilify MyCite (aripiprazole tablets with the sensor, Otsuka Pharmaceutical), Caplyta (lumateperone, Intra-Cellular Therapies), Secuado (asenapine/HP-3070, Noven Pharmaceuticals/Hisamitsu Pharmaceutical), Invega Sustenna (paliperidone palmitate, Janssen Pharmaceuticals), Adasuve (loxapine, Alexza Pharmaceuticals/Teva Pharmaceuticals), Invega Trinza (Janssen Pharmaceuticals), and several others.

Recently in December 2019, the USFDA approved Caplyta (lumateperone/ ITI-007), a new oral medicine for the treatment of schizophrenia of adults. The mechanism of action of caplyta in the treatment of schizophrenia is unknown. However, the efficacy of caplyta could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. In November 2017, Intra-Cellular Therapies received FDA Fast Track Designation for lumateperone for the treatment of schizophrenia.

Moreover, in October 2019, the US FDA approved the Secuado (asenapine/HP-3070) transdermal system-the first-and-only transdermal patch formulation-for the treatment of adults with schizophrenia. Asenapine is a second-generation atypical antipsychotic, currently available as a sublingual formulation for the treatment of schizophrenia in adults.

Key Findings

  • The market size of Schizophrenia in the 7MM was USD 6,066.97 million in 2017.
  • Among the EU-5 countries, Germany, has the highest market size followed by the UK, and France. The lowest market size was estimated in Spain in 2017.
  • The current management of Schizophrenia is categorized into first-generation antipsychotics and second-generation antipsychotics. These are further categorized based on the route of administration, as oral, injectables, and other (sublingual, and transdermal patches). Due to more efficacy and comparative high cost, injectables occupy majority of the market share.
  • The market share developed by first-generation antipsychotics and second-generation antipsychotics in the year 2017 was USD 516.78 million, and USD 5,336.18 million, respectively in the 7MM.
  • The market size of injectables and orals of second-generation antipsychotics class, was estimated to be USD 3,191.83 million, and USD 2,065.91 million, respectively in 2017, in the 7MM.

Market Outlook for Seven Major Markets

This section provides the total Schizophrenia market size and market size by therapies in the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

Schizophrenia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that are expected to get launched in the market during the study period 2017-2030. The analysis covers Schizophrenia market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Schizophrenia Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Schizophrenia emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Schizophrenia market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Schizophrenia, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
  • Comprehensive insight has been provided into the Schizophrenia epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Schizophrenia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Schizophrenia market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Schizophrenia market.

Report Highlights:

  • The Schizophrenia market is anticipated to increase for the study period 2017-2030.
  • Perseris (risperidone) projected to lead the market with the largest market share in 2030.
  • In the coming years, Schizophrenia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Schizophrenia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Schizophrenia. Launch of emerging therapies will significantly impact the Schizophrenia market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Schizophrenia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Schizophrenia Pipeline Analysis
  • Schizophrenia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Schizophrenia Report Key Strengths

  • 11-Years Forecast
  • 7MMCoverage
  • Schizophrenia Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Schizophrenia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Schizophrenia market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Schizophrenia total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Schizophrenia market size during the forecast period (2020-2030)?
  • At what CAGR, the Schizophrenia market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Schizophrenia market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Schizophrenia market growth until 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Schizophrenia?
  • What is the historical Schizophrenia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of Schizophrenia at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Schizophrenia?
  • Out of the countries mentioned above, which country would have the highest number of Schizophrenia cases during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Schizophrenia along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Schizophrenia in the US and Europe?
  • What are the Schizophrenia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Schizophrenia?
  • How many therapies are developed by each company for the treatment of Schizophrenia?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Schizophrenia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Schizophrenia therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Schizophrenia and their status?
  • What are the key designations that have been granted for the emerging therapies for Schizophrenia?
  • What are the 7MM historical and forecasted market of Schizophrenia?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Schizophrenia.
  • To understand the future market competition in the Schizophrenia market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Schizophrenia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Schizophrenia market.
  • To understand the future market competition in the Schizophrenia market.

Table of Contents
Product Code: DIMI0015

Table of Contents

1. Key Insights

2. Executive Summary of Schizophrenia

3. Schizophrenia Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of Schizophrenia in 2017
  • 3.2. Market Share (%) Distribution of Schizophrenia in 2030

4. Disease Background and Overview: Schizophrenia

  • 4.1. Introduction
  • 4.2. Early warning signs and symptoms of schizophrenia
  • 4.3. Risk factors of schizophrenia
  • 4.4. Subtypes of schizophrenia
  • 4.5. Mechanism of schizophrenia
  • 4.6. Genetics of schizophrenia
  • 4.7. Diagnosis
  • 4.8. Differential Diagnosis

5. Case Reports

  • 5.1. Remission of psychosis in treatment-resistant schizophrenia following bone marrow transplantation: A case report
  • 5.2. Case on akathisia in an elderly female patient with schizophrenia upon concurrent use of risperidone and sertraline
  • 5.3. Case Study: A young male with auditory hallucinations in paranoid schizophrenia

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. KOL Views
  • 6.3. Epidemiology Methodology
  • 6.4. Total Prevalent Cases of Schizophrenia in the 7MM
  • 6.5. Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM

7. United States Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Prevalent Cases of schizophrenia in the United States
  • 7.3. Diagnosed Prevalent cases of schizophrenia in the United States
  • 7.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in the United States
  • 7.5. Age-specific Diagnosed Prevalent cases of schizophrenia in the United States
  • 7.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in the United States

8. EU5 Epidemiology

  • 8.1. Germany Epidemiology
    • 8.1.1. Assumptions and Rationale
    • 8.1.2. Prevalent Cases of schizophrenia in Germany
    • 8.1.3. Diagnosed Prevalent cases of schizophrenia in Germany
    • 8.1.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Germany
    • 8.1.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Germany
    • 8.1.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Germany
  • 8.2. France Epidemiology
    • 8.2.1. Assumptions and Rationale
    • 8.2.2. Prevalent Cases of schizophrenia in France
    • 8.2.3. Diagnosed Prevalent cases of schizophrenia in France
    • 8.2.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in France
    • 8.2.5. Age-specific Diagnosed Prevalent cases of schizophrenia in France
    • 8.2.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in France
  • 8.3. Italy Epidemiology
    • 8.3.1. Assumptions and Rationale
    • 8.3.2. Prevalent Cases of schizophrenia in Italy
    • 8.3.3. Diagnosed Prevalent cases of schizophrenia in Italy
    • 8.3.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Italy
    • 8.3.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Italy
    • 8.3.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Italy
  • 8.4. Spain Epidemiology
    • 8.4.1. Assumptions and Rationale
    • 8.4.2. Prevalent Cases of schizophrenia in Spain
    • 8.4.3. Diagnosed Prevalent cases of schizophrenia in Spain
    • 8.4.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Spain
    • 8.4.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Spain
    • 8.4.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Spain
  • 8.5. United Kingdom Epidemiology
    • 8.5.1. Assumptions and Rationale
    • 8.5.2. Prevalent Cases of schizophrenia in the UK
    • 8.5.3. Diagnosed Prevalent cases of schizophrenia in the UK
    • 8.5.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in the UK
    • 8.5.5. Age-specific Diagnosed Prevalent cases of schizophrenia in the UK
    • 8.5.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in the UK

9. Japan Epidemiology

  • 9.1. Assumptions and Rationale
  • 9.2. Prevalent Cases of schizophrenia in Japan
  • 9.3. Diagnosed Prevalent cases of schizophrenia in Japan
  • 9.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Japan
  • 9.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Japan
  • 9.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Japan

10. Treatment

  • 10.1. Acute-phase symptoms
  • 10.2. Pre-treatment assessment
  • 10.3. Medication (Antipsychotic)
  • 10.4. Psychotherapy
  • 10.5. Psychosocial Therapy
  • 10.6. Electroconvulsive Therapy (ECT)
  • 10.7. IPAP schizophrenia Algorithm
  • 10.8. Treatment guidelines
    • 10.8.1. The American Psychiatric Association (APA) practice guideline for the treatment of patients with schizophrenia
    • 10.8.2. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations
    • 10.8.3. Updated schizophrenia port treatment recommendations: psychosocial treatment recommendations

11. Unmet needs

12. Marketed Drugs

  • 12.1. Key Cross
  • 12.2. Rexulti (brexpiprazole/OPC-34712): Otsuka America Pharmaceutical/Lundbeck
    • 12.2.1. Drug Description
    • 12.2.2. Mechanism of Action
    • 12.2.3. Regulatory Milestones
    • 12.2.4. Clinical Development
    • 12.2.5. Safety and Efficacy
    • 12.2.6. Product Profile
  • 12.3. Caplyta (lumateperone/ITI-007): Intra-Cellular Therapies
    • 12.3.1. Drug Description
    • 12.3.2. Mechanism of Action
    • 12.3.3. Regulatory Milestones
    • 12.3.4. Clinical Development
    • 12.3.5. Safety and Efficacy
    • 12.3.6. Product Profile
  • 12.4. Latuda (lurasidone hydrochloride): Sunovion Pharmaceuticals/ Sumitomo Dainippon Pharma
    • 12.4.1. Drug Description
    • 12.4.2. Mechanism of Action
    • 12.4.3. Regulatory Milestones
    • 12.4.4. Clinical Development
    • 12.4.5. Safety and Efficacy
    • 12.4.6. Product Profile
  • 12.5. Saphris (asenapine): Merck/AbbVie/Schering-Plough Corporation/Allergan
    • 12.5.1. Drug Description
    • 12.5.2. Mechanism of Action
    • 12.5.3. Regulatory Milestones
    • 12.5.4. Safety and Efficacy
    • 12.5.5. Product Profile
  • 12.6. Abilify MyCite (aripiprazole tablets with sensor): Otsuka Pharmaceutical
    • 12.6.1. Drug Description
    • 12.6.2. Mechanism of Action
    • 12.6.3. Regulatory Milestones
    • 12.6.4. Clinical Development
    • 12.6.5. Safety and Efficacy
    • 12.6.6. Product Profile
  • 12.7. Invega Sustenna (paliperidone palmitate): Janssen Research & Development
    • 12.7.1. Product Description
    • 12.7.2. Regulatory Milestones
    • 12.7.3. Clinical Development
    • 12.7.4. Safety and Efficacy
    • 12.7.5. Product Profile
  • 12.8. Vraylar/Reagila (cariprazine): Gedeon Richter/AbbVie
    • 12.8.1. Drug Description
    • 12.8.2. Regulatory Milestones
    • 12.8.3. Clinical Development
    • 12.8.4. Safety and Efficacy
    • 12.8.5. Product Profile
  • 12.9. Adasuve (loxapine): Alexza Pharmaceuticals
    • 12.9.1. Product Description
    • 12.9.2. Regulatory Milestones
    • 12.9.3. Clinical Development
    • 12.9.4. Safety and Efficacy
    • 12.9.5. Product Profile
  • 12.10. Secuado (asenapine/HP-3070): Noven Pharmaceuticals/Hisamitsu Pharmaceutical
    • 12.10.1. Drug Description
    • 12.10.2. Regulatory Milestones
    • 12.10.3. Clinical Development
    • 12.10.4. Safety and Efficacy
    • 12.10.5. Product Profile
  • 12.11. Invega Trinza: Janssen Pharmaceuticals
    • 12.11.1. Drug Description
    • 12.11.2. Regulatory Milestones
    • 12.11.3. Clinical Development
    • 12.11.4. Safety and Efficacy
    • 12.11.5. Product Profile
  • 12.12. Aristada and Aristada Initio: Alkermes
    • 12.12.1. Drug Description
    • 12.12.2. Mechanism of Action
    • 12.12.3. Regulatory Milestones
    • 12.12.4. Clinical Development
    • 12.12.5. Safety and Efficacy
    • 12.12.6. Product Profile
  • 12.13. Perseris (risperidone): Indivior
    • 12.13.1. Drug Description
    • 12.13.2. Mechanism of Action
    • 12.13.3. Regulatory Milestones
    • 12.13.4. Clinical Development
    • 12.13.5. Safety and Efficacy
    • 12.13.6. Product Profile

13. Emerging Drugs

  • 13.1. Key Cross Competition
  • 13.2. Doria (risperidone ISM): Rovi Pharmaceuticals Laboratories
    • 13.2.1. Product Description
    • 13.2.2. Other Developmental Activities
    • 13.2.3. Clinical Development
    • 13.2.4. Safety and Efficacy
    • 13.2.5. Product Profile
  • 13.3. Roluperidone (MIN-101): Minerva Neurosciences
    • 13.3.1. Product Description
    • 13.3.2. Other Developmental Activities
    • 13.3.3. Clinical Development
    • 13.3.4. Safety and Efficacy
    • 13.3.5. Product Profile
  • 13.4. SEP-363856: Sunovion/PsychoGenics
    • 13.4.1. Product Description
    • 13.4.2. Other Developmental Activities
    • 13.4.3. Clinical Development
    • 13.4.4. Safety and Efficacy
    • 13.4.5. Product Profile
  • 13.5. Pimavanserin: Acadia Pharmaceuticals
    • 13.5.1. Product Description
    • 13.5.2. Other developmental activity
    • 13.5.3. Clinical Development
    • 13.5.4. Safety and Efficacy
    • 13.5.5. Product Profile
  • 13.6. Encenicline (EVP-6124): Forum Pharmaceuticals
    • 13.6.1. Product Description
    • 13.6.2. Other developmental activity
    • 13.6.3. Clinical Development
    • 13.6.4. Safety and Efficacy
    • 13.6.5. Product Profile
  • 13.7. Dexmedetomidine (BXCL501): BioXcel Therapeutics
    • 13.7.1. Product Description
    • 13.7.2. Other Developmental Activities
    • 13.7.3. Clinical Development
    • 13.7.4. Safety and Efficacy
    • 13.7.5. Product Profile
  • 13.8. Avisetron (AVN-211): Avineuro Pharmaceuticals
    • 13.8.1. Product Description
    • 13.8.2. Other Developmental Activity
    • 13.8.3. Clinical Development
    • 13.8.4. Safety and Efficacy
    • 13.8.5. Product Profile
  • 13.9. ALKS 3831 (Olanzapine + Samidorphan): Alkermes
    • 13.9.1. Product Description
    • 13.9.2. Other Developmental Activities
    • 13.9.3. Clinical Development
    • 13.9.4. Safety and Efficacy
    • 13.9.5. Product Profile
  • 13.10. AVP-786: Avanir Pharmaceuticals/Otsuka Pharmaceutical/Concert Pharmaceuticals
    • 13.10.1. Product Description
    • 13.10.2. Other Developmental Activities
    • 13.10.3. Clinical Development
    • 13.10.4. Product Profile
  • 13.11. Lu AF11167: H. Lundbeck A/S
    • 13.11.1. Product Description
    • 13.11.2. Other Developmental Activities
    • 13.11.3. Clinical Development
    • 13.11.4. Product Profile
  • 13.12. GWP42003 (Cannabidiol/GWP42003-P): GW Research
    • 13.12.1. Product Description
    • 13.12.2. Clinical Development
    • 13.12.3. Safety and Efficacy
    • 13.12.4. Product Profile
  • 13.13. BI 409306: Boehringer Ingelheim
    • 13.13.1. Product Description
    • 13.13.2. Other Developmental Activities
    • 13.13.3. Clinical Development
    • 13.13.4. Safety and Efficacy
    • 13.13.5. Product Profile
  • 13.14. KarXT: Karuna Pharmaceuticals
    • 13.14.1. Product Description
    • 13.14.2. Other developmental activity
    • 13.14.3. Clinical Development
    • 13.14.4. Safety and Efficacy
    • 13.14.5. Product Profile
  • 13.15. TAK-831: Takeda
    • 13.15.1. Product Description
    • 13.15.2. Other Developmental Activities
    • 13.15.3. Clinical Development
    • 13.15.4. Product Profile
  • 13.16. NaBen (Sodium Benzoate): SyneuRx International
    • 13.16.1. Product Description
    • 13.16.2. Other Developmental Activities
    • 13.16.3. Clinical Development
    • 13.16.4. Product Profile
  • 13.17. BI 425809: Boehringer Ingelheim
    • 13.17.1. Product Description
    • 13.17.2. Other developmental activity
    • 13.17.3. Clinical Development
    • 13.17.4. Safety and Efficacy
    • 13.17.5. Product Profile
  • 13.18. BIIB104 (AMPA): Biogen
    • 13.18.1. Product Description
    • 13.18.2. Other developmental activity
    • 13.18.3. Clinical Development
    • 13.18.4. Safety and Efficacy
    • 13.18.5. Product Profile
  • 13.19. RO6889450: Roche
    • 13.19.1. Product Description
    • 13.19.2. Clinical Development
    • 13.19.3. Product Profile
  • 13.20. PF-06412562: Cerevel Therapeutics/Pfizer
    • 13.20.1. Product Description
    • 13.20.2. Other developmental activity
    • 13.20.3. Clinical Development
    • 13.20.4. Safety and Efficacy
    • 13.20.5. Product Profile
  • 13.21. CTP-692: Concert Pharmaceuticals
    • 13.21.1. Product Description
    • 13.21.2. Other Developmental Activity
    • 13.21.3. Clinical Development
    • 13.21.4. Product Profile
  • 13.22. Evenamide (NW-3509/NW-3509A): Newron Pharmaceuticals
    • 13.22.1. Product Description
    • 13.22.2. Other Developmental Activity
    • 13.22.3. Clinical Development
    • 13.22.4. Safety and Efficacy
    • 13.22.5. Product Profile
  • 13.23. Miricorilant: Corcept Therapeutics
    • 13.23.1. Product Description
    • 13.23.2. Clinical Development
    • 13.23.3. Product Profile
  • 13.24. MK-8189: Merck
    • 13.24.1. Product Description
    • 13.24.2. Clinical Development
    • 13.24.3. Product Profile
  • 13.25. CPL500036: Celon Pharma
    • 13.25.1. Product Description
    • 13.25.2. Other Developmental Activities
    • 13.25.3. Clinical Development
    • 13.25.4. Safety and Pharmacokinetics
    • 13.25.5. Product Profile

14. Key Endpoints

15. Schizophrenia: 7MM Market Analysis

  • 15.1. Key Findings
  • 15.2. Market Methodology
  • 15.3. Attribute Analysis
  • 15.4. Market Size of Schizophrenia in the 7MM
  • 15.5. Market Size of Schizophrenia by Therapies in the 7MM
    • 15.5.1. Market Size of Schizophrenia by Class in the 7MM
    • 15.5.2. Market Size of Schizophrenia by Current and Emerging Therapies in the 7MM

16. United States Market Outlook

  • 16.1. United States Market Size
  • 16.2. Total market size of Schizophrenia in the United States
  • 16.3. Market Size of Schizophrenia by Therapies in the US

17. EU-5 Market Outlook

  • 17.1. Germany Market Size
    • 17.1.1. Total Market size of Schizophrenia in Germany
    • 17.1.2. Market Size of Schizophrenia by Therapies in Germany
  • 17.2. France Market Size
    • 17.2.1. Total Market size of Schizophrenia in France
    • 17.2.2. Market Size of Schizophrenia by Therapies in France
  • 17.3. Italy Market Size
    • 17.3.1. Total Market size of Schizophrenia in Italy
    • 17.3.2. Market Size of Schizophrenia by Therapies in Italy
  • 17.4. Spain Market Size
    • 17.4.1. Total Market size of Schizophrenia in Spain
    • 17.4.2. Market Size of Schizophrenia by Therapies in Spain
  • 17.5. United Kingdom Market Size
    • 17.5.1. Total Market size of Schizophrenia in the United Kingdom
    • 17.5.2. Market Size of Schizophrenia by Therapies in the UK

18. Japan Market Outlook

  • 18.1. Japan Market Size
    • 18.1.1. Total Market size of Schizophrenia in Japan
    • 18.1.2. Market Size of Schizophrenia by Therapies in Japan

19. Key Market Forecast Assumptions

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Reimbursement and Market Access

24. Appendix

  • 24.1. Bibliography
  • 24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

List of Tables

  • Table 1 Summary of Schizophrenia, Market, Epidemiology and Key Events (2017-2030)
  • Table 2 Early symptoms of schizophrenia
  • Table 3 Symptoms of Schizophrenia
  • Table 4 Clinical features of schizophrenia, bipolar disorder, schizoaffective disorder, autism, and ADHD
  • Table 5 Total Prevalent Cases of Schizophrenia in the 7MM (2017-2030)
  • Table 6 Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM (2017-2030)
  • Table 7 Prevalent cases of schizophrenia in the United States (2017-2030)
  • Table 8 Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Table 9 Gender-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Table 10 Age-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Table 11 Severity-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Table 12 Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 13 Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 14 Gender-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 15 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 16 Severity-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 17 Prevalent cases of schizophrenia in France (2017-2030)
  • Table 18 Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Table 19 Gender-specific Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Table 20 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 21 Severity-specific Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Table 22 Prevalent cases of schizophrenia in Italy (2017-2030)
  • Table 23 Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Table 24 Gender-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Table 25 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 26 Severity-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Table 27 Prevalent cases of schizophrenia in Spain (2017-2030)
  • Table 28 Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Table 29 Gender-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Table 30 Age-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Table 31 Severity-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Table 32 Prevalent cases of schizophrenia in the UK (2017-2030)
  • Table 33 Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Table 34 Gender-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Table 35 Age-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Table 36 Severity-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Table 37 Prevalent cases of schizophrenia in Japan (2017-2030)
  • Table 38 Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Table 39 Gender-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Table 40 Age-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Table 41 Severity-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Table 42 Antipsychotic medications: available oral and short-acting intramuscular formulations and dosing considerations
  • Table 43 Long-acting injectable antipsychotic medications: dosing
  • Table 44 Key Cross of Marketed Drugs
  • Table 45 Rexulti (brexpiprazole), Clinical Trial Description, 2020
  • Table 46 Caplyta (lumateperone/ ITI-007), Clinical Trial Description, 2020
  • Table 47 Latuda, Clinical Trial Description, 2020
  • Table 48 Abilify MyCite, Clinical Trial Description, 2020
  • Table 49 Invega Sustenna (paliperidone palmitate), Clinical Trial Description, 2020
  • Table 50 Vraylar, Clinical Trial Description, 2020
  • Table 51 Adasuve, Clinical Trial Description, 2020
  • Table 52 Secuado, Clinical Trial Description, 2020
  • Table 53 Invega Trinza, Clinical Trial Description, 2020
  • Table 54 Somatuline Depot (lanreotide acetate), Clinical Trial Description, 2020
  • Table 55 Perseris, Clinical Trial Description, 2020
  • Table 56 Key Cross of Emerging Drug
  • Table 57 Doria (risperidone ISM), Clinical Trial Description, 2020
  • Table 58 Roluperidone, Clinical Trial Description, 2020
  • Table 59 SEP-363856, Clinical Trial Description, 2020
  • Table 60 Pimavanserin, Clinical Trial Description 2020
  • Table 61 EVP-6124, Clinical Trial Description
  • Table 62 BXCL501, Clinical Trial Description, 2020
  • Table 63 ALKS 3831, Clinical Trial Description, 2020
  • Table 64 AVP-786, Clinical Trial Description, 2020
  • Table 65 Lu AF11167, Clinical Trial Description, 2020
  • Table 66 GWP42003 (Cannabidiol/GWP42003-P), Clinical Trial Description, 2020
  • Table 67 BI 409306, Clinical Trial Description, 2020
  • Table 68 KarXT, Clinical Trial Description
  • Table 69 TAK-831, Clinical Trial Description, 2020
  • Table 70 NaBen (Sodium Benzoate), Clinical Trial Description, 2020
  • Table 71 BI 425809, Clinical Trial Description 2020
  • Table 72 BIIB104, Clinical Trial Description 2020
  • Table 73 RO6889450, Clinical Trial Description
  • Table 74 PF 06412562, Clinical Trial Description
  • Table 75 CTP-692; Clinical Trial Description,2020
  • Table 76 Evenamide, Clinical Trial Description,2020
  • Table 77 Miricorilant (CORT118335), Clinical Trial Description, 2020
  • Table 78 MK-8189, Clinical Trial Description, 2020
  • Table 79 MK-8189, Clinical Trial Description, 2020
  • Table 80 Market Size of Schizophrenia in the 7MM in USD Million (2017-2030)
  • Table 81 Market Size of Schizophrenia by Class in the 7MM, in USD Million (2017-2030)
  • Table 82 Market Size of Schizophrenia by Current and Emerging Therapies in the 7MM, in USD Million (2017-2030)
  • Table 83 The US Market Size of Schizophrenia in USD Million (2017-2030)
  • Table 84 Market Size of Schizophrenia by Therapies in the US, in USD Million (2017-2030)
  • Table 85 Market Size of Schizophrenia by Current and Emerging Therapies in the US, in USD Million (2017-2030)
  • Table 86 Germany Market Size of Schizophrenia in USD Million (2017-2030)
  • Table 87 Market Size of Schizophrenia by Therapies in Germany, in USD Million (2017-2030)
  • Table 88 Market Size of Schizophrenia by Current and Emerging Therapies in Germany, in USD Million (2017-2030)
  • Table 89 France Market Size of Schizophrenia in USD Million (2017-2030)
  • Table 90 Market Size of Schizophrenia by Class in France, in USD Million (2017-2030)
  • Table 91 Market Size of Schizophrenia by Current and Emerging Therapies in France, in USD Million (2017-2030)
  • Table 92 Italy Market Size of Schizophrenia in USD Million (2017-2030)
  • Table 93 Market Size of Schizophrenia by Class in Italy, in USD Million (2017-2030)
  • Table 94 Market Size of Schizophrenia by Current and Emerging Therapies in Italy, in USD Million (2017-2030)
  • Table 95 Spain Market Size of Schizophrenia in USD Million (2017-2030)
  • Table 96 Market Size of Schizophrenia by Therapies in Spain, in USD Million (2017-2030)
  • Table 97 Market Size of Schizophrenia by Current and Emerging Therapies in Spain, in USD Million (2017-2030)
  • Table 98 The UK Market Size of Schizophrenia in USD Million (2017-2030)
  • Table 99 Market Size of Schizophrenia by Class in the UK, in USD Million (2017-2030)
  • Table 100 Market Size of Schizophrenia by Current and Emerging Therapies in the UK, in USD Million (2017-2030)
  • Table 101 Japan Market Size of Schizophrenia in USD Million (2017-2030)
  • Table 102 Market Size of Schizophrenia by Class in Japan, in USD Million (2017-2030)
  • Table 103 Market Size of Schizophrenia by Current and Emerging Therapies in Japan, in USD Million (2017-2030)
  • Table 104 Key Market Forecast Assumptions for Roluperidone (MIN-101)
  • Table 105 Key Market Forecast Assumptions for Dexmedetomidine (BXCL501)
  • Table 106 Key Market Forecast Assumptions for SEP363856
  • Table 107 Key Market Forecast Assumptions for Pimavanserin
  • Table 108 Key Market Forecast Assumptions for Risperidone ISM (DORIA)
  • Table 109 Key Market Forecast Assumptions for ALKS 3831
  • Table 110 Key Market Forecast Assumptions for Evenamide
  • Table 111 Key Market Forecast Assumptions for BI 409306
  • Table 112 Key Market Forecast Assumptions for GWP42003-P
  • Table 113 Key Market Forecast Assumptions for KarXT

List of Figures

  • Figure 1 Overview of Schizophrenia
  • Figure 2 Interaction of genetic and environmental risk factors in the developmental pathology of schizophrenia
  • Figure 3 Neuron-glia interactions in the cerebral cortex-key neural substrates for the pathology of schizophrenia
  • Figure 4 Schematic representation of drug actions that normalize aberrant glutamate neurotransmission in the prefrontal cortex of schizophrenics
  • Figure 5 A representative molecular pathway for schizophrenia-fine-tuning of the glutamate synapse
  • Figure 6 KOL Views
  • Figure 7 KOL Views
  • Figure 8 Total Prevalent Cases of Schizophrenia in the 7MM (2017-2030)
  • Figure 9 Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM (2017-2030)
  • Figure 10 Prevalent cases of schizophrenia in the United States (2017-2030)
  • Figure 11 Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Figure 12 Gender-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Figure 13 Age-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Figure 14 Severity-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Figure 15 Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 16 Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 17 Gender-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 18 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 19 Severity-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 20 Prevalent cases of schizophrenia in France (2017-2030)
  • Figure 21 Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Figure 22 Gender-specific Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Figure 23 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 24 Severity-specific Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Figure 25 Prevalent cases of schizophrenia in Italy (2017-2030)
  • Figure 26 Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Figure 27 Gender-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Figure 28 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 29 Severity-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Figure 30 Prevalent cases of schizophrenia in Spain (2017-2030)
  • Figure 31 Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Figure 32 Gender-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Figure 33 Age-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Figure 34 Severity-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Figure 35 Prevalent cases of schizophrenia in the UK (2017-2030)
  • Figure 36 Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Figure 37 Gender-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Figure 38 Age-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Figure 39 Severity-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Figure 40 Prevalent cases of schizophrenia in Japan (2017-2030)
  • Figure 41 Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Figure 42 Gender-specific Diagnosed Prevalent cases of schizophrenia in Japan(2017-2030)
  • Figure 43 Age-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Figure 44 Severity-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Figure 45 Treatment approaches of schizophrenia
  • Figure 46 Types of medications to treat schizophrenia
  • Figure 47 Types of Psychotherapy to treat schizophrenia
  • Figure 48 Schizophrenia Algorithm
  • Figure 49 Unmet Needs of Schizophrenia
  • Figure 50 Atypical antipsychotics, or second-generation antipsychotic drugs
  • Figure 51 Market Size of Schizophrenia in the 7MM in USD Million (2017-2030)
  • Figure 52 Market Size of Schizophrenia by Class in the 7MM, in USD Million (2017-2030)
  • Figure 53 Market Size of Schizophrenia by Current and Emerging Therapies in the 7MM, in USD Million (2017-2030)
  • Figure 54 Market Size of Schizophrenia in the US, USD Millions (2017-2030)
  • Figure 55 Market Size of Schizophrenia by Class in the US, in USD Million (2017-2030)
  • Figure 56 Market Size of Schizophrenia by Current and Emerging Therapies in the US, in USD Million (2017-2030)
  • Figure 57 Market Size of Schizophrenia in Germany, USD Millions (2017-2030)
  • Figure 58 Market Size of Schizophrenia by Class in Germany, in USD Million (2017-2030)
  • Figure 59 Market Size of Schizophrenia by Current and Emerging Therapies in Germany, in USD Million (2017-2030)
  • Figure 60 Market Size of Schizophrenia in France, USD Millions (2017-2030)
  • Figure 61 Market Size of Schizophrenia by Class in France, in USD Million (2017-2030)
  • Figure 62 Market Size of Schizophrenia by Current and Emerging Therapies in France, in USD Million (2017-2030)
  • Figure 63 Market Size of Schizophrenia in Italy, USD Millions (2017-2030)
  • Figure 64 Market Size of Schizophrenia by Class in Italy, in USD Million (2017-2030)
  • Figure 65 Market Size of Schizophrenia by Current and Emerging Therapies in Italy in USD Million (2017-2030)
  • Figure 66 Market Size of Schizophrenia in Spain, USD Millions (2017-2030)
  • Figure 67 Market Size of Schizophrenia by Class in Spain in USD Million (2017-2030)
  • Figure 68 Market Size of Schizophrenia by Current and Emerging Therapies in Spain in USD Million (2017-2030)
  • Figure 69 Market Size of Schizophrenia in the UK, USD Millions (2017-2030)
  • Figure 70 Market Size of Schizophrenia by Class in the UK in USD Million (2017-2030)
  • Figure 71 Market Size of Schizophrenia by Current and Emerging Therapies in the UK in USD Million (2017-2030)
  • Figure 72 Market Size of Schizophrenia in Japan, USD Millions (2017-2030)
  • Figure 73 Market Size of Schizophrenia by Class in Japan, in USD Million (2017-2030)
  • Figure 74 Market Size of Schizophrenia by Molecules of Different Class in Japan in USD Million (2017-2030)
  • Figure 75 Market Drivers
  • Figure 76 Market Barriers
  • Figure 77 SWOT Analysis of Schizophrenia
Back to Top